NCT03824236View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

April 30, 2019

Study Completion Date

September 26, 2019

Conditions
Malaria
Interventions
BIOLOGICAL

RTS,S/AS01E (SB257049)

Subjects from the P-Fx and NP-Fx groups will receive one Fx booster dose of RTS,S/AS01E at Day 1.

Trial Locations (1)

20910

GSK Investigational Site, Silver Spring

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
collaborator

PATH

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT03824236 - A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults | Biotech Hunter | Biotech Hunter